Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ceftobiprole in Neonates and Infants
NCT02527681Phase 1Terminated
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of ceftobiprole medocaril in bacterial infection, sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Plasma Concentration at 12 hours, Time to Maximum Concentration at 12 hours and 2 more. Started Nov 2016; status: terminated.
02
Drugs
ceftobiprole medocaril
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02527681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527681.